CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
Revenue	$ 0	$ 1,061,000
Costs and expenses:
Patient expenses	0	86,000
Selling, general and administrative	1,386,000	1,063,000
Total	1,386,000	1,149,000
Operating loss	(1,386,000)	(88,000)
Total other (expense) income
Interest expense	0	(3,000)
Interest income - sales-type sublease	0	8,000
Loss from loans to unconsolidated entities	(163,000)	(451,000)
Gain (loss) from investments in unconsolidated entities, net	16,000	(19,000)
Total other expense	(147,000)	(465,000)
Loss before income taxes	(1,533,000)	(553,000)
Income tax provision	(39,000)	(420,000)
Net loss	(1,572,000)	(973,000)
Net loss attributable to noncontrolling interests	235,000	92,000
Net loss attributable to U.S. Neurosurgical Holdings, Inc.	$ (1,337,000)	$ (881,000)
Basic net loss per share attributable to U.S. NeuroSurgical Holdings, Inc. (in dollars per share)	$ (0.17)	$ (0.11)
Diluted net loss per share attributable to U.S. NeuroSurgical Holdings, Inc. (in dollars per share)	$ (0.17)	$ (0.11)
Weighted average common shares outstanding, basic (in shares)	7,842,185	7,792,185
Weighted average common shares outstanding, diluted (in shares)	7,842,185	7,792,185